Navigation Links
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Date:6/1/2009

ed to patients treated at lower doses (167 days versus 83 days). These observations are in line with data from a previous phase 2 trial investigating adecatumumab as a single agent in MBC patients that also suggested that treatment with adecatumumab was associated with better outcome in patients with high EpCAM expression compared to patients with low EpCAM expression(2). Micromet is currently also conducting a randomized phase 2 clinical trial with adecatumumab in patients with colorectal cancer after complete resection of liver metastases.

"These data indicate that adding adecatumumab to standard chemotherapy is feasible," said Carsten Reinhardt, M.D., Ph.D., senior vice president and chief medical officer of Micromet. "The combination of adecatumumab with taxanes could be a valuable development option for MBC patients with high EpCAM expression on their tumors, and would offer an antibody-based therapy to those patients who express EpCAM but not Her-2 and thus do not qualify for Her-2-targeting antibody therapy."

(1) Sebastian, M. et al. (2009). Safety and anti-tumor activity of 3-weekly anti-EpCAM antibody adecatumumab (MT201) in combination with docetaxel for patients with metastatic breast cancer: Results of a multicenter phase Ib trial. ASCO meeting abstract no. 1009.

(2) Schmidt, M. et al. (2009). An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology, in press.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that act
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
2. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
3. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
4. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
5. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
6. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
7. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
8. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
9. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
10. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
11. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... According to market research report ... Controllers; Wireless gateways)]- Global Advancements, Forecasts and Analysis ... Outdoor Wi-Fi market with analysis and forecasting of ... identifies the drivers and the restrains for this ... and challenges. , Browse 65 market data tables ...
(Date:10/18/2014)... The Asia-Pacific Bio-based Advanced Phase Change Materials Market ... change material market in Asia-Pacific with analysis and ... of the Asia-Pacific Bio-based Advanced Phase Change Materials ... in-depth analysis provided. This also provides a glimpse ... phase change material market, and is supported by ...
(Date:10/18/2014)... The Asian arthroscopic devices report defines and segments the ... revenue. The arthroscopic devices market in Asia is estimated ... CAGR of 6.5% from 2013 to 2018. , Browse ... to get an idea of the in-depth analysis provided. ... arthroscopic devices market in the same region, and is ...
(Date:10/18/2014)... 2014 The Asia-Pacific Liquid Crystal on ... concerned market in Asia-Pacific with analysis and forecast of ... 2013, and is expected to reach $380.0 million by ... 2018. , Browse through the TOC of the Asia-Pacific ... the in-depth analysis provided. This also provides a glimpse ...
Breaking Biology Technology:Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 4The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3
... SAN DIEGO, Feb. 26 Ambrx Inc. today ... as Senior Vice President,for Clinical Research and Development., ... spanning nearly two,decades at Procter & Gamble Pharmaceuticals. ... for Discovery, Early Development and Product,Development where he ...
... NATICK, Mass., Feb. 26 Boston Scientific,Corporation (NYSE: ... Ph.D.,will be joining the Company,s Clinical Sciences organization effective,March ... and Associate Chief Medical,Officer, sitting on the Clinical Leadership ... Dr. Donald S. Baim, M.D. In his new role,Dr. ...
... Feb. 26 BioStorage Technologies, Inc.,(BST), announces the ... the company,s European operations in Griesheim, Germany. Hoffer,joins ... in the fields of,clinical pharmacology and toxicology. In ... M. Saponaro, Chief Operating Officer for BST, and ...
Cached Biology Technology:Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development 2Boston Scientific Announces Addition to Clinical Sciences Organization 2Boston Scientific Announces Addition to Clinical Sciences Organization 3Boston Scientific Announces Addition to Clinical Sciences Organization 4BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations 2
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
(Date:10/14/2014)... A Mount Sinai-led research team has discovered a new kind ... or a cell that lines liver blood vessels, according to ... Reports . The existence of such a cell type contradicts ... the embryo, and may hold clues to origins of, and ... develop from a single cell into a complex being made ...
(Date:10/14/2014)... team of scientists led by researchers at the ... University of Miami Miller School of Medicine (UMMSM) ... pathway underlying bipolar (manic depressive) disorder, a breakthrough ... bipolar affective disorder, as well as depression and ... published online this week in Nature Molecular ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... (April 19, 2010) Virginia Commonwealth University researchers have ... key role in the development of liver cancer. Levels ... than 90 percent of patients with the disease compared ... Virginia Commonwealth University Massey Cancer Center and the VCU ...
... Md. (April 19, 2010) Chesapeake Biological Laboratory Director ... of Maryland Center for Environmental Science with its President,s ... informing policymakers and the public about the environmental impacts ... Dr. Palmer seeks to expand the impact of her ...
... metals or semiconductors to soft organic or biological products. Picture ... Mother Nature. The applications in medicine and manufacturing ... of nanoscience at The Florida State University. How ... chip" that can diagnose illness? That and much more are ...
Cached Biology News:Researchers identify new gene involved in the development of liver cancer 2UMCES ecologist Margaret Palmer recognized for promoting the role of science in public policy 2Bionanotechnology has new face, world-class future at Florida State 2Bionanotechnology has new face, world-class future at Florida State 3
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
Sprague Dawley rats, 7-8 weeks of age, mixed gender; collected by exsanguination in Alsever's solution at 1:2 dilution...
... The S.c. EasyComp Transformation Kit ... transformation-competent Saccharomyces cerevisiae cells. Advantages over ... spheroplast formation or LiCl methods include:- Cells ... than 30 minutes - Competent cell preparation ...
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
Biology Products: